Abstract
In this open-label, randomized, multiple-dose, two-treatment crossover study, 24 postmenopausal women with moderate to severe atrophic vaginitis received 0.3 mg conjugated estrogens daily for 14 days: 7 days orally (0.3 mg tablet) and 7 days vaginally (0.5 g cream). Steady-state plasma concentrations of E2 and estrone were one-third lower after vaginal versus oral administration of conjugated estrogens.
Copyright © 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.
Publication types
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Administration, Intravaginal
-
Administration, Oral
-
Aged
-
Atrophy / blood
-
Atrophy / drug therapy
-
Atrophy / metabolism
-
Cross-Over Studies
-
Drug Administration Schedule
-
Estradiol / blood*
-
Estrogens, Conjugated (USP) / administration & dosage*
-
Estrogens, Conjugated (USP) / blood
-
Estrogens, Conjugated (USP) / pharmacokinetics
-
Estrone / blood
-
Female
-
Humans
-
Middle Aged
-
Osmolar Concentration
-
Vagina / drug effects
-
Vagina / pathology*
-
Vaginal Creams, Foams, and Jellies
-
Vaginitis / blood
-
Vaginitis / drug therapy*
-
Vaginitis / metabolism
Substances
-
Estrogens, Conjugated (USP)
-
Vaginal Creams, Foams, and Jellies
-
Estrone
-
Estradiol